

Press Release

31 October 2008

e-Therapeutics plc

("e-Therapeutics" or "the Company")

Director's shareholding

e-Therapeutics plc (AIM: ETX), the systems biology drug discovery company, announces that on 29 October, 2008, Professor Oliver James acquired, in aggregate, 23,500 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at an average price of 41p per share. Following this acquisition, Professor Oliver James is interested in 23,500 Ordinary Shares, which represents 0.04% of the current issued share capital of the Company.

- ENDS -

For further information:

e-Therapeutics plc

www.etherapeutics.co.uk

Malcolm Young

+44 (0) 191 233 1317

malcolm@etherapeutics.co.uk

Nominated Advisor:

WH Ireland

Katy Mitchell

+44 (0)113 394 6628

katy.mitchell@wh-ireland.co.uk

Broker:

Cornhill Capital

Tom Whitehead

+44 (0) 207 337 1247

tomw@cornhillcapital.com

Andrew Houchin

+44 (0) 207 337 1247

andrewh@cornhillcapital.com



e-Therapeutics plc

Media enquiries:

Abchurch

www.abchurch-group.com

Heather Salmond

Tel: +44 (0) 20 7398 7704

heather.salmond@abchurch-group.com

Stephanie Cuthbert

Tel: +44 (0) 20 7398 7718

stephanie.cuthbert@abchurch-group.com

Simone Alves

Tel: +44 (0) 20 7398 7728

simone.alves@abchurch-group.com

Notes to Editors

e-Therapeutics plc is a systems biology drug discovery company. It has developed proprietary computational systems to swiftly and accurately analyse and predict how medicines interact with cells in the body. This optimises the probability of identifying drug candidates with desirable efficacy and low toxicity. The Company applies its novel, systematic approach to three areas of activity:

- discovery of new drugs;
- discovering novel uses for existing drugs; and
- analysis of the interactions between different drugs.

Amongst e-Therapeutics' pipeline of compounds in development are novel antibiotics that have been shown to kill the "superbug" MRSA, and a novel cancer chemotherapy that has been shown to kill malignant cells at safe doses in a very short time. Other candidate therapies in development are targeted at atherosclerosis, asthma and depression. The Company is currently in negotiation with a number of pharmaceutical companies, and is progressing the preclinical and clinical development of these products.

For further information on e-Therapeutics visit www.etherapeutics.co.uk.